PYY(3-36) and semaglutide in rat MASLD

A 2026 laboratory study found that combining PYY(3-36) with semaglutide produced stronger changes in several liver and mitochondrial measures than either treatment alone in male rats with diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD)^[1]. The result is preclinical. It does not show that this combination treats MASLD in people, establish a safe human dose, or support combining peptide products outside a clinical trial.

The experiment compared semaglutide, PYY(3-36), the two together, food restriction and saline control over eight weeks after an eight-week disease-induction period. The combination group showed reduced mitochondrial respiration, lower mitochondrial hydrogen-peroxide production and less hepatocellular stress. Those outcomes help researchers examine possible biological pathways. They are not clinical endpoints such as symptom improvement, avoidance of cirrhosis or longer survival.

What the PYY(3-36) and semaglutide study tested

The researchers first fed male Wistar rats a high-fat, high-fructose diet and gave them L-NAME for eight weeks. They then randomized the animals to semaglutide (10 rats), PYY(3-36) (7), the combination (10), food restriction (4), or saline control (17) for another eight weeks^[2]. Group sizes were small and unequal. The food-restriction comparator was especially small, which matters when interpreting the reported absence of a significant effect in that group.

PYY(3-36) is a form of peptide YY that acts at the neuropeptide Y2 receptor. Semaglutide acts at the GLP-1 receptor. The paper examined whether those distinct signalling routes might produce complementary effects in liver tissue. It measured mitochondrial oxygen consumption and peroxide emission, assessed liver staining for lipid storage and injury-related changes, and analysed gene-expression pathways. This design addresses mechanism in an animal model rather than treatment effectiveness in patients.

What changed in liver and mitochondrial measures

The abstract reports that semaglutide and PYY(3-36) each mitigated hepatic inflammation and the histological MASLD score, with additive effects in the combination group. RNA sequencing showed downregulation of pathways involved in oxidative phosphorylation and beta-oxidation. Oxidative-phosphorylation-related genes were reduced in the combination group, in line with the mitochondrial-respirometry findings^[2]. These are tissue, molecular and laboratory outcomes measured after the intervention period.

The authors described the combination as producing superior effects on selected measures: mitochondrial respiration declined, mitochondrial hydrogen-peroxide production decreased, and hepatocellular stress was reduced. A decline in respiration should not be translated into a simple claim that mitochondria became universally better or worse. In this paper, it sits within a broader pattern of reduced oxidative stress and liver injury in the model. The measurements require the authors' experimental context rather than a consumer-facing wellness interpretation.

Why the food-restriction comparison is interesting but limited

The researchers included a food-restriction group to examine whether weight loss alone reproduced the mitochondrial changes. The abstract says food restriction and weight loss had no significant effect on mitochondrial respiration or genes regulating oxidative phosphorylation. That finding supports further study of mechanisms beyond weight change. It does not prove that weight loss is irrelevant to MASLD, nor does it isolate every difference between food restriction and drug exposure.

Only four rats were assigned to food restriction. A non-significant result in such a small group cannot demonstrate that two approaches are equivalent or that one mechanism has been excluded. The experiment also involved a particular diet, L-NAME exposure, male rats and an eight-week treatment window. Each choice narrows how confidently the result can be extended to other models, female animals, longer follow-up or human disease.

What this rat result does not say about MASLD care

Nothing in this paper establishes PYY(3-36) plus semaglutide as a human MASLD treatment. Readers looking for clinical context can review our semaglutide guide and our report on the semaglutide and MASH evidence review. Our semaglutide safety overview provides medicine-specific context. The present study did not enroll people, compare clinical liver outcomes, or test whether adding PYY(3-36) improves benefits enough to offset additional risks.

Animal-model findings often help identify pathways worth testing, but translation can fail for many reasons. Human MASLD varies with diabetes status, fibrosis stage, other illnesses and concurrent treatment. A laboratory measure can move without producing a meaningful patient benefit. Conversely, an intervention can affect several pathways while also causing harms that a small animal experiment was not designed to characterize.

What we do not yet know

The PubMed record and abstract do not provide human efficacy or safety data for this combination. They do not establish whether the reported mitochondrial pattern would occur in people, whether it would persist after treatment stopped, or whether it would reduce progression to advanced liver disease. The study also cannot determine a clinically appropriate dose, treatment duration or monitoring plan. Those questions require staged human research rather than extrapolation from rat groups.

The abstract does not report broad long-term safety assessment, rare adverse events or reproductive outcomes. It also leaves uncertainty about how each molecular change contributes to the overall histological result. Future work would need replication, larger and more varied animal cohorts, and carefully designed human trials. A useful human trial would need patient-relevant liver outcomes and prospective safety collection, not only changes in laboratory markers.

The result supports mechanism research, not self-treatment

This 48-rat study offers a specific mechanistic signal: PYY(3-36) appeared to add to semaglutide's effects on selected liver and mitochondrial measures in this model. The strongest interpretation stays close to that design. It is evidence for investigating GLP-1 and neuropeptide-Y2 receptor pathways together, not evidence that people should seek or combine these substances. Treatment decisions for MASLD should be based on approved options, a person's disease stage and clinical guidance.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.